HomeHLN • LON
Haleon PLC
GBX 393.99
Sep 27, 2:25:52 PM GMT+1 · GBX · LON · Disclaimer
StockGB listed security
Previous close
GBX 390.10
Day range
GBX 388.40 - GBX 395.40
Year range
GBX 308.37 - GBX 400.65
Market cap
35.91B GBP
Avg Volume
19.34M
P/E ratio
33.51
Dividend yield
1.57%
Primary exchange
LON
CDP Climate Change Score
B
Financials
Income Statement
Revenue
Net income
(GBP)Jun 2024Y/Y change
Revenue
2.78B0.84%
Operating expense
1.15B5.58%
Net income
303.00M1.68%
Net profit margin
10.920.83%
Earnings per share
0.10-7.02%
EBITDA
718.50M3.08%
Effective tax rate
22.91%—
Total assets
Total liabilities
(GBP)Jun 2024Y/Y change
Cash and short-term investments
531.00M8.37%
Total assets
33.40B-2.25%
Total liabilities
16.69B-5.16%
Total equity
16.71B—
Shares outstanding
9.13B—
Price to book
2.14—
Return on assets
——
Return on capital
6.16%—
Net change in cash
(GBP)Jun 2024Y/Y change
Net income
303.00M1.68%
Cash from operations
——
Cash from investing
——
Cash from financing
——
Net change in cash
——
Free cash flow
——
About
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022. Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Sir David Lewis is chairman, with Brian McNamara as CEO. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020. Wikipedia
Founded
Jul 18, 2022
Website
Employees
25,408
Search
Clear search
Close search
Google apps
Main menu